Visit https://www.peervoice.com/XAD860 to view the entire programme with slides. After completing “Marla C. Dubinsky, MD / David T. Rubin, MD - TNF Inhibitors in Inflammatory Bowel Disease: How Can We Realize Opportunities to Optimize Clinical and Patient Outcomes?”, participants will be able to: Recall the evidence of the impact of tumor necrosis factor (TNF) inhibitors on endoscopic outcomes in patients with inflammatory bowel disease (IBD); Use clinical data to illustrate the potential benefits of early intervention with; TNF inhibitors in patients with IBD; Explain the importance of maintaining a steady, stable serum drug level during maintenance treatment of IBD with a TNF inhibitor; and Apply recommended approaches for effective and safe management of patients receiving TNF inhibitor-based maintenance therapy that optimizes both clinical and patient outcomes.

Visit https://www.peervoice.com/YQY860 to view the entire programme with slides. After completing “Olivier Bonnot, MD, PhD - Acute Psychosis: When to Suspect Acute Hepatic Porphyria”, participants will be able to: Recognise acute hepatic porphyria (AHP) in patients with acute psychosis; Identify patients with psychological symptoms who should be screened for AHP; and Describe the importance of a multidisciplinary team approach in the management of patients with AHP.

Visit https://www.peervoice.com/UDS860 to view the entire programme with slides. After completing “Darren M. Brenner / Benoît Coffin - If I'd Known Then What I Know Now: Recognising My First AHP Patient”, participants will be able to: Describe uncommon causes of unexplained abdominal pain; Recognise acute hepatic porphyria (AHP) in patients with severe abdominal pain; and Discuss the importance of random (spot) urine testing in patients with suspected AHP.

Visit https://www.peervoice.com/HJY860 to view the entire programme with slides. After completing “Darren M. Brenner, MD - If I'd Known Then What I Know Now: Recognising My First AHP Patient (Rebroadcast)”, participants will be able to: Describe uncommon causes of unexplained abdominal pain; Recognise acute hepatic porphyria (AHP) in patients with severe abdominal pain; and Discuss the importance of random (spot) urine testing in patients with suspected AHP.

Visit https://www.peervoice.com/GHB860 to view the entire programme with slides. After completing “Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding”, participants will be able to: Evaluate current guideline recommendations for management of life-threatening bleeding associated with anticoagulation use; Assess data from clinical trials and real-world studies related to specific anticoagulation reversal strategies for factor Xa-associated bleeding; and Identify patient-specific characteristics that may influence choice of a management strategy for life-threatening bleeding associated with anticoagulation.

Visit https://www.peervoice.com/GWC860 to view the entire programme with slides. After completing “Philip James Tozer, MBBS, MD(Res), FRCS - Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring the Who, When, and How for Stem Cell Therapy”, participants will be able to: Evaluate efficacy and safety outcomes for advanced therapies, including stem cell therapy, which guide their incorporation into treatment plans for patients with complex perianal fistulas (CPF) due to Crohn’s disease (CD); Identify the role of magnetic resonance imaging in the assessment of CPF and treatment response in patients with CD; and Propose multidisciplinary care plans for patients with CPF due to CD.

Visit https://www.peervoice.com/TKB860 to view the entire programme with slides. After completing “Andreas Kremer, MD, PhD, MHBA - Initiating the Conversation on Itch: Modelling Best Practices in Patient-Centred Care for Cholestatic Pruritus in PBC”, participants will be able to: Describe the impact of uncontrolled cholestatic pruritus on patient quality of life, mental health, and overall outcomes in primary biliary cholangitis (PBC); Summarise key patient counselling and education points related to cholestatic pruritus in PBC; and Incorporate effective communication and information-gathering strategies to improve evaluation of cholestatic pruritus in PBC.

Visit https://www.peervoice.com/KQF860 to view the entire programme with slides. After completing “Andreas Kremer, MD, PhD, MHBA - Incorporating the Investigation of Itch Into the Patient Care Process for PBC: Practical Steps, Tips, and Tools”, participants will be able to: Recognise the consequences of uncontrolled cholestatic pruritus on quality of life and outcomes in patients with primary biliary cholangitis (PBC); Demonstrate ability to use effective strategies when discussing and evaluating cholestatic pruritus in patients with PBC; and Evaluate both current and novel investigational strategies for management of cholestatic pruritus.

Visit https://www.peervoice.com/GSQ860 to view the entire programme with slides. After completing “David T. Rubin, MD, AGAF - What They Say and What They Think: Exploring Tools for Assessing Bowel Urgency in Patients with Ulcerative Colitis”, participants will be able to: Discuss latest evidence on bowel urgency in patients with ulcerative colitis (UC) and its influence on quality of life; Analyze current communication gaps between patients with UC and clinicians during clinic visits; and Recognize the benefits and limitations of current patient-reported outcomes tools.

Visit https://www.peervoice.com/EJU860 to view the entire programme with slides. After completing “Marla C. Dubinsky, MD - Most Patients With Ulcerative Colitis ‘Can’t Wait’: The Impact and Clinical Assessment of Bowel Urgency”, participants will be able to: Discuss recent data regarding bowel urgency experienced by patients with UC and the impact on QoL; Describe how bowel urgency is linked to poor clinical outcomes, biomarkers, and disease activity; and Recognise the benefits and limitations of current PRO tools for bowel urgency and create innovative communication techniques based on real-world experience.

Visit https://www.peervoice.com/ZBV860 to view the entire programme with slides. After completing “Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics”, participants will be able to: Summarise key findings from the 24-month analysis of the ENVISION trial in patients with acute hepatic porphyria (AHP); Discuss the current practices and unmet needs for the long-term management of AHP; and Describe the impact of these data on clinical practice within the context of treatment paradigms for the long-term management of patients with AHP.

Visit https://www.peervoice.com/CCV860 to view the entire programme with slides. After completing “Advanced Therapy for CPF in Crohn's: Evaluating the Evidence for Stem Cell Therapy and More”, participants will be able to: Summarise key findings from the literature on advanced treatment options for complex perianal fistula (CPF) in Crohn’s disease; Review the strengths and limitations of these data in the context of current practice for CPF; and Describe the impact of these data on clinical practice.

Visit https://www.peervoice.com/UAB860 to view the entire programme with slides. After completing “How I Treat: Achieving Healing in CPF”, participants will be able to: Explain the rationale for stem cell therapy in complex perianal fistulas (CPF) due to Crohn’s disease, based on disease pathophysiology; Establish goals of therapy for patients with CPF based on desired outcomes, such as fistula healing; and Formulate treatment plans for CPF based on short- and long-term goals of therapy.

Visit https://www.peervoice.com/UEF860 to view the entire programme with slides. After completing “Perspectives on the Management of CPF: Moving the Goalposts With Shared Decision-Making”, participants will be able to: Summarise unmet needs with traditional therapies for complex perianal fistulas (CPF) due to Crohn’s disease (CD); Develop a patient-centred model of care to improve communication and collaboration among the multidisciplinary team, including facilitating referral to specialty IBD centres; and Apply best practices to facilitate access to care in order to achieve fistula healing.

Visit https://www.peervoice.com/TMJ860 to view the entire programme with slides. After completing “Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics”, participants will be able to: Summarise key findings from the 24-month analysis of the ENVISION trial in patients with acute hepatic porphyria (AHP); Discuss the current practices and unmet needs for the long-term management of AHP; and Describe the impact of these data on clinical practice within the context of treatment paradigms for the long-term management of patients with AHP.

Visit https://www.peervoice.com/QYZ860 to view the entire programme with slides. After completing “Shining a Light on the Treatment of Primary Hyperoxaluria 1: Does the Evidence Improve Our Options?”, participants will be able to: Summarise key findings from published studies evaluating RNA interference (RNAi) targeting glycolate oxidase in patients with primary hyperoxaluria type 1 (PH1); Discuss the strengths and limitations of these studies in light of current practices for the management of PH1; Describe the impact of these data on clinical practice within the context of current and future treatment paradigms for PH1.